233 related articles for article (PubMed ID: 30086875)
1. Genetic causes and treatment of neonatal diabetes and early childhood diabetes.
Barbetti F; D'Annunzio G
Best Pract Res Clin Endocrinol Metab; 2018 Aug; 32(4):575-591. PubMed ID: 30086875
[TBL] [Abstract][Full Text] [Related]
2. Monogenic Forms of Diabetes Mellitus.
Gaál Z; Balogh I
Exp Suppl; 2019; 111():385-416. PubMed ID: 31588541
[TBL] [Abstract][Full Text] [Related]
3. Monogenic Diabetes Accounts for 6.3% of Cases Referred to 15 Italian Pediatric Diabetes Centers During 2007 to 2012.
Delvecchio M; Mozzillo E; Salzano G; Iafusco D; Frontino G; Patera PI; Rabbone I; Cherubini V; Grasso V; Tinto N; Giglio S; Contreas G; Di Paola R; Salina A; Cauvin V; Tumini S; d'Annunzio G; Iughetti L; Mantovani V; Maltoni G; Toni S; Marigliano M; Barbetti F;
J Clin Endocrinol Metab; 2017 Jun; 102(6):1826-1834. PubMed ID: 28323911
[TBL] [Abstract][Full Text] [Related]
4. ABCC8-related maturity-onset diabetes of the young: switching from insulin to sulphonylurea therapy: how long do we need for a good metabolic control?
Evin F; Işık E; Onay H; Özen S; Darcan Ş; Gökşen D
J Pediatr Endocrinol Metab; 2023 Jun; 36(6):592-597. PubMed ID: 37071846
[TBL] [Abstract][Full Text] [Related]
5. Maturity onset diabetes of the young: identification and diagnosis.
McDonald TJ; Ellard S
Ann Clin Biochem; 2013 Sep; 50(Pt 5):403-15. PubMed ID: 23878349
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young.
Ellard S; Colclough K
Hum Mutat; 2006 Sep; 27(9):854-69. PubMed ID: 16917892
[TBL] [Abstract][Full Text] [Related]
7. Monogenic models: what have the single gene disorders taught us?
Klupa T; Skupien J; Malecki MT
Curr Diab Rep; 2012 Dec; 12(6):659-66. PubMed ID: 22996131
[TBL] [Abstract][Full Text] [Related]
8. Next generation sequencing targeted gene panel in Greek MODY patients increases diagnostic accuracy.
Tatsi EB; Kanaka-Gantenbein C; Scorilas A; Chrousos GP; Sertedaki A
Pediatr Diabetes; 2020 Feb; 21(1):28-39. PubMed ID: 31604004
[TBL] [Abstract][Full Text] [Related]
9. High Incidence of Heterozygous ABCC8 and HNF1A Mutations in Czech Patients With Congenital Hyperinsulinism.
Rozenkova K; Malikova J; Nessa A; Dusatkova L; Bjørkhaug L; Obermannova B; Dusatkova P; Kytnarova J; Aukrust I; Najmi LA; Rypackova B; Sumnik Z; Lebl J; Njølstad PR; Hussain K; Pruhova S
J Clin Endocrinol Metab; 2015 Dec; 100(12):E1540-9. PubMed ID: 26431509
[TBL] [Abstract][Full Text] [Related]
10. Genetic and Clinical Characterization of Patients with Maturity-Onset of Diabetes of the Young (MODY): Identification of Novel Variations.
Ateş EA; Üstay Ö; Polat H; Apaydın T; Elbasan O; Yıldırım Ö; Güney Aİ
Balkan Med J; 2021 Sep; 38(5):272-277. PubMed ID: 34462253
[TBL] [Abstract][Full Text] [Related]
11. Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds.
Zhang M; Chen X; Shen S; Li T; Chen L; Hu M; Cao L; Cheng R; Zhao Z; Luo F
J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):877-84. PubMed ID: 25781672
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry.
Johansson BB; Irgens HU; Molnes J; Sztromwasser P; Aukrust I; Juliusson PB; Søvik O; Levy S; Skrivarhaug T; Joner G; Molven A; Johansson S; Njølstad PR
Diabetologia; 2017 Apr; 60(4):625-635. PubMed ID: 27913849
[TBL] [Abstract][Full Text] [Related]
13. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort.
Bacon S; Kyithar MP; Rizvi SR; Donnelly E; McCarthy A; Burke M; Colclough K; Ellard S; Byrne MM
Diabet Med; 2016 Jul; 33(7):976-84. PubMed ID: 26479152
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics and target identification in diabetes.
Pearson ER
Curr Opin Genet Dev; 2018 Jun; 50():68-73. PubMed ID: 29486427
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of monogenic diabetes in the population-based Norwegian Childhood Diabetes Registry.
Irgens HU; Molnes J; Johansson BB; Ringdal M; Skrivarhaug T; Undlien DE; Søvik O; Joner G; Molven A; Njølstad PR
Diabetologia; 2013 Jul; 56(7):1512-9. PubMed ID: 23624530
[TBL] [Abstract][Full Text] [Related]
16. A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea.
Jesić MD; Sajić S; Jesić MM; Maringa M; Micić D; Necić S
Diabetes Res Clin Pract; 2008 Jul; 81(1):e1-3. PubMed ID: 18433912
[TBL] [Abstract][Full Text] [Related]
17. Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities.
Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
Diabetes Metab Syndr; 2012; 6(1):54-8. PubMed ID: 23014256
[TBL] [Abstract][Full Text] [Related]
18. Clinical presentation and long-term outcome of patients with KCNJ11/ABCC8 variants: Neonatal diabetes or MODY in the DPV registry from Germany and Austria.
Warncke K; Eckert A; Kapellen T; Kummer S; Raile K; Dunstheimer D; Grulich-Henn J; Woelfle J; Wenzel S; Hofer SE; Dost A; Holl RW
Pediatr Diabetes; 2022 Nov; 23(7):999-1008. PubMed ID: 35822653
[TBL] [Abstract][Full Text] [Related]
19. A successful transition to sulfonylurea treatment in male infant with neonatal diabetes caused by the novel abcc8 gene mutation and three years follow-up.
Katanic D; Vorgučin I; Hattersley A; Ellard S; Houghton JAL; Obreht D; Knežević Pogančev M; Vlaški J; Pavkov D
Diabetes Res Clin Pract; 2017 Jul; 129():59-61. PubMed ID: 28511139
[TBL] [Abstract][Full Text] [Related]
20. Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype.
Garcin L; Mericq V; Fauret-Amsellem AL; Cave H; Polak M; Beltrand J
Pediatr Diabetes; 2020 Sep; 21(6):932-941. PubMed ID: 32418263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
